menu
    • menu

    Company profile for Astellas Pharma

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Astellas Pharma Inc., to fulfill its business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," is actively engaged in business as an R&D-driven global pharmaceutical company. We wish to be of help to each patient who is fighting illness by continuously generating innovative and highly beneficial drugs for diseases which ...
    Astellas Pharma Inc., to fulfill its business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," is actively engaged in business as an R&D-driven global pharmaceutical company. We wish to be of help to each patient who is fighting illness by continuously generating innovative and highly beneficial drugs for diseases which high unmet medical needs exist, through continuous efforts in research and development, and providing them.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Astellas Pharmajapan Flag
    Country
    Country
    Japan
    Address
    Address
    2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411
    Telephone
    Telephone
    +81-3-3244-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.astellas.com/en/about
    Linkedin
    Linkedin
    https://www.linkedin.com/company/astellas-pharma-singapore/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/astellaspharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Not Confirmed

    envelop Contact Supplier

    CPhI China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 1152

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaProviding RSMs & API to Global Pharma CompaniesProviding RSMs & API to Global Pharma Companies

    Providing RSMs & API to Global Pharma Companies
    Providing RSMs & API to Global Pharma Companies

    reelProviding RSMs & API to Global Pharma Companies

    This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

    Impressions: 5

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    The pharmaceutical excipients market saw significant strategic consolidations, technological developments, and regulatory adaptations in 2025. Globally, the pharmaceutical excipients sector is growing at a compound annual growth rate of 6.6 percent, and was valued at US$ 8.85 billion in 2024. It is projected to reach US$ 14.77 billion by 2032.This year, the sector is witnessing technological advancements, regulatory evolution, and strategic business realignments. North America continues to dominate the global excipients landscape, with a 39.8 percent market share. The Asia-Pacific region is the fastest-growing segment with a substantial 30.4 percent market share, driven by increasing investments in pharmaceutical manufacturing, growing demand for cost-effective drugs, and rising healthcare expenditure across developing economies.Major excipient providers include BASF, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, DuPont, Evonik, Seqens, Actylis, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Kewpie Corporation, Boai NKY Pharmaceuticals, ICE Pharma, Roquette, Nanjing Well Pharmaceutical, Minakem, Ashland Global, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Roquette restructures after buying IFF Pharma; Colorcon partners ASHA CelluloseIn May, Roquette completed its acquisition of IFF Pharma Solutions. Valued at up to US$ 2.85 billion in enterprise value, this transaction represents a major consolidation in the pharmaceutical excipients market. The acquisition significantly enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide. Roquette announced a comprehensive, new organizational structure following the acquisition, indicating the company’s commitment to integrate IFF Pharma Solutions’ capabilities seamlessly into its existing operations. This consolidation creates a more robust platform for addressing the growing demand for specialized excipients in complex drug formulations, particularly as the industry moves towards more personalized approaches to medicines.So far, the year has also witnessed some strategic alliances, such as Colorcon’s partnership with ASHA Cellulose. As part of the deal, Colorcon will become the exclusive representative for two ASHA products — ASHACEL and ASHAKOTE — throughout Europe, the Middle East, Africa, Northeast Asia and Southeast Asia.Brenntag Specialties has announced an exclusive distribution agreement with MEGGLE Excipients to expand market reach. This collaboration makes available a broad portfolio of over 30 high-quality lactose-based excipients for various applications in the pharmaceutical industries across the Netherlands, Belgium, Norway, Finland, and Sweden.The portfolio’s versatility offers optimal solutions for a wide range of pharmaceutical applications, including tableting through both granulation and direct compression, powder preparations, and dry powder inhalation. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)WHO, FDA drive new standards with GMP guidelines; Pfanstiehl launches injectable-grade glycineIn March, the World Health Organization had put out a publication titled “Good Manufacturing Practices for Excipients used in Pharmaceutical Products.” WHO’s excipient GMP guideline emphasizes modern quality management principles, comprehensive risk assessment protocols, and supplier qualification procedures for excipients across all stages of production, storage, and distribution.Meanwhile, the US Food and Drug Administration (FDA) has proposed amendments to the Food, Drug, and Cosmetic Act as part of its FY 2025 legislative proposals, specifically targeting supply chain transparency for high-risk excipients. The FDA proposal would require certain excipients designated as high-risk to carry labeling that identifies the original manufacturer’s name and address. This initiative addresses what FDA has identified as a lack of transparency in excipient supply chains.In April, IFF Pharma Solutions launched Low Nitrite METHOCEL hydroxypropyl methylcellulose (HPMC). This innovative product is specifically designed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages, addressing one of the most pressing concerns in contemporary pharmaceutical manufacturing.Pfanstiehl, a global leader in high-purity excipient manufacturing, announced the launch of its High Purity Low Endotoxin Low Metals (HPLE-LM) injectable-grade glycine. This multi-compendial glycine is specifically engineered for use in biologics, vaccines, and the downstream purification of monoclonal antibodies (mAbs). Manufactured under ICH-Q7 cGMP regulations at Pfanstiehl’s advanced facility in Waukegan, Illinois, the product meets stringent global pharmacopeial standards. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Shin-Etsu Chemical invests in Japan, Germany to expand cellulose productionIn March, Shin-Etsu Chemical announced investments in pharmaceutical cellulose business operations in Japan and Europe, thereby showing significant commitment to market expansion. The company is making substantial investments at two key bases: the subsidiary SE Tylose GmbH in Germany, and the Naoetsu Plant in Joetsu, Japan. In Germany, a new production facility for the pharmaceutical excipient L-HPC will be built adjacent to the existing facility, creating a dual base with the Naoetsu Plant. The excipients market in 2025 has seen innovation in functional applications. Research on BENEO’s Palatinose as a bedtime drink shows that it improves aspects of sleep and represents an innovative approach to excipient functionality. Palatinose is a naturally sourced, smart carbohydrate that provides full carbohydrate energy in a more balanced way, thanks to its low-glycemic profile.Gangwal Healthcare, with its EXCiPACT-certified GMP facilities and a robust portfolio of co-processed excipients like ProBlend, Starlose, and Microlose, is actively contributing to the pharmaceutical industry’s demand for functional excipients. The company also offers cellulose-based excipients such as Solvostar (Sodium Starch Glycolate) and Sallyso (Croscarmellose Sodium), designed to improve tablet disintegration and drug release profiles in oral solid dosage forms.Evonik announced a partnership with South Korea–based CDMO ST Pharm to expand its RNA and nucleic acid delivery services. This collaboration enables Evonik to integrate customized nucleic acids from ST Pharm seamlessly with its lipid and lipid nanoparticle (LNP) development and fill-and-finish services. This streamlined approach means that pharmaceutical companies can reduce complexity and increase speed-to-market for nucleic acid therapeutics. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Our viewThe pharmaceutical excipients market in 2025 is being shaped by several key trends including the development of multifunctional excipients that can simultaneously improve solubility, bioavailability, and control drug release in increasingly complex formulations.Moreover, the expanding generic medicines market is creating demand for cost-effective, versatile excipients. The growing importance of biologics and biosimilars is driving innovation in specialized excipients designed to maintain the stability and efficacy of these complex therapeutic products throughout their lifecycle. And nanotechnology continues to enable advanced nano-excipients for enhanced drug delivery and efficacy.In addition to these trends, we also notice a shift towards natural and plant-based excipients that is driven by sustainability concerns and potential biocompatibility benefits. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1667

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks

    #PharmaFlow by PHARMACOMPASS
    29 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Astellas`s Biologics Vyloy Receives Suppl Approval in US
    Astellas`s Biologics Vyloy Receives Suppl Approval in US

    06 Jun 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365

    FDA
    06 Jun 2025
    Share Share
    Astellas aims for CLDN18.2 gold with $1.34B licensing deal
    Astellas aims for CLDN18.2 gold with $1.34B licensing deal

    29 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html

    PR NEWSWIRE
    29 May 2025
    Share Share
    Astellas Launches PAO Week To Support Patients
    Astellas Launches PAO Week To Support Patients

    28 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-announces-second-annual-patient-advocacy-organization-pao-action-week-to-empower-patients-and-caregivers-302467137.html

    PR NEWSWIRE
    28 May 2025
    Share Share
    Astellas and Pfizer's Xtandi shows long-term survival in Cancer
    Astellas and Pfizer's Xtandi shows long-term survival in Cancer

    22 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-and-pfizers-xtandi-enzalutamide-shows-long-term-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-302463546.html

    PR NEWSWIRE
    22 May 2025
    Share Share
    Astellas Awards 2025 Prize to DeepSeq.AI, Serna Bio
    Astellas Awards 2025 Prize to DeepSeq.AI, Serna Bio

    21 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-and-mbc-biolabs-announce-the-2025-astellas-future-innovator-prize-awarded-to-deepseqai--serna-bio-302461230.html

    PR NEWSWIRE
    21 May 2025
    Share Share
    Astellas Presents New Data on Cancer Therapies at ASCO Meeting
    Astellas Presents New Data on Cancer Therapies at ASCO Meeting

    19 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-presents-new-data-that-explores-potential-of-its-cancer-therapies-at-2025-asco-annual-meeting-302458480.html

    PR NEWSWIRE
    19 May 2025
    Share Share

    USDMF

    read-more
    read-more

    01

    (tiaramide Hcl) General Procedures

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    02

    Cefazolin

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    03

    Cefazolin Sodium (sterile)

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    04

    Cefixime

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    05

    Cefotetan

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    06

    Cephalosporin (oral) (fk482 Cefdinir...

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    07

    Cephalosprin C Fermentation And Reco...

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    08

    Famotidine

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    09

    Famotidine

    Japan
    FCE Pharma
    Not Confirmed
    arrow

    10

    Fk-037 Drug Substance (injectable Ce...

    Japan
    FCE Pharma
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Cefixime

    CEP/COS

    FCE Pharma
    Not Confirmed
    arrow

    02

    Cefixime

    CEP/COS

    FCE Pharma
    Not Confirmed
    arrow

    03

    Ceftizoxime sodium

    CEP/COS

    FCE Pharma
    Not Confirmed
    arrow

    04

    Tamsulosin hydrochloride

    CEP/COS

    FCE Pharma
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Prograf

    JDMF

    FCE Pharma
    Not Confirmed
    arrow

    Prograf

    Japan
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Astellas Pharma

    Registration Number : 217MF11288

    Registrant's Address : 2-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo

    Initial Date of Registration : 2005-12-22

    Latest Date of Registration : 2007-09-10

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    Clinical Trials

    Click here to discover the service providers for Clinical Trials

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact ASTELLAS PHARMA CANADA INC and get a quotation

    ASTELLAS PHARMA CANADA INC is a supplier offers 44 products (APIs, Excipients or Intermediates).

    Find a price of Tacrolimus bulk with DMF, JDMF offered by ASTELLAS PHARMA CANADA INC

    Find a price of Tamsulosin bulk with CEP offered by ASTELLAS PHARMA CANADA INC

    Find a price of Cefixime bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Famotidine bulk with DMF offered by ASTELLAS PHARMA CANADA INC

    Find a price of Micafungin bulk with DMF offered by ASTELLAS PHARMA CANADA INC

    Find a price of Cefazolin bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Cefazolin Sodium bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Cefotetan bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Ceftizoxime Sodium bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Cephalosporin bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Famotidine bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Fk-330 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Fk962 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Formoterol Fumarate bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Nilvadipine bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Rhizoxin bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Tamoxifen Citrate bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Tamsulosin bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Tiaramide Hydrochloride bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Vancomycin Hydrochloride bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Zotepine bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of SYNTHESIS OF PYRROINITRIN bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FACILITY IN TOYOMA, JAPAN bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of 7 ACA-A48 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK366 ALDOSE REDUCTASE INHIBITOR bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK1706 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK778 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK-866 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK317 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FACILITY LOCATED IN OSAKA, JAPAN bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK973 DRUG SUBSTANCE AND DRUG PRODUCT IN AICHI & OSAKA, JAPAN bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK555 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK117 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK8453 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of YM087 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FACILITY LOCATED IN NAGOYA, JAPAN bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK506 (FK900506) DOSAGE FORMS bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK 881 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK 788 DRUG SUBSTANCE bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of FK 960 bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Isavuconazonium Sulfate bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Mirabegron bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Ramosetron HCl bulk offered by ASTELLAS PHARMA CANADA INC

    Find a price of Solifenacin Succinate bulk offered by ASTELLAS PHARMA CANADA INC

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search